An innovative collaboration model designed to accelerate next-generation precision cancer immunotherapy through network of leading research centers and top scientists
CRI iAtlas to provide immune bioinformatics tool that aims to improve cancer immunotherapy research and drug effectiveness.
The two nonprofits partnered to support four scientists whose research is focused on developing immunotherapies for patients with fibrolamellar hepatocellular carcinoma.
Researchers at 30 organizations to test algorithms that predict tumor markers from DNA in hunt for new personalized cancer treatments.
Help CRI win the $1 million grand prize.
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, 4th Floor | New York, NY 10006-3111
(800) 992-2623(212) 832-9376Staff Directory
Immunotherapy tripled the median progression-free survival rate among lung cancer patients compared to those who received only chemotherapy and radiation
We introduce you to Thomas Hudson, M.D., vice president, head of oncology discovery and early development at AbbVie.